Canvaxin Melanoma Vaccine BLA Delayed Until 2007 After Trial Fails

Serono/CancerVax data safety monitoring board recommends halting Phase III development of Canvaxin for Stage IV melanoma due to lack of efficacy. Pivotal program for Stage III disease continues; no safety issues were identified with either study.